Study of ARO-ANG3 in Adults With Mixed Dyslipidemia | NCT04832971

Label	Type	Description	Intervention Names
ARO-ANG3 50 mg	Experimental	Two doses of ARO-ANG3 by subcutaneous (sc) injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.	Drug: ARO-ANG3
ARO-ANG3 100 mg	Experimental	Two doses of ARO-ANG3 bysc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.	Drug: ARO-ANG3
ARO-ANG3 200 mg	Experimental	Two doses of ARO-ANG3 by sc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.	Drug: ARO-ANG3
Placebo	Placebo Comparator	Calculated volume to match active treatment by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.	Drug: ARO-ANG3 Drug: Placebo

Name	Type	Description	Arm Group Labels	Other Names
ARO-ANG3	Drug	ARO-ANG3 Injection	ARO-ANG3 100 mg ARO-ANG3 200 mg ARO-ANG3 50 mg Placebo

Measure	Description	Time Frame
Percent Change From Baseline in Fasting TG at Week 24		Baseline, Week 24

Measure	Description	Time Frame
Percent Change From Baseline in Fasting TG Over Time		Baseline, up to Week 36 (double-blind treatment period)
Percent Change From Baseline in Fasting Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24		Baseline, Week 24

Facility	Status	City	State	ZIP	Country	Contacts
Research Site 5		Huntington Park	California	90255	United States
Research Site 7

PubMed Identifier	Type	Citation	Retractions
38809174	Derived	Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, San Martin J, Zhou R, Muhsin M, Chang T, Hellawell J, Watts GF; ARCHES-2 Trial Team. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024 Sep 12;391(10):913-925. doi: 10.1056/NEJMoa2404147. Epub 2024 May 29.
38682459

ID	Title	Description
FG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
FG001	ARO-ANG3 50 mg

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot	Yes	No	No	Study Protocol	Nov 22, 2022	Nov 29, 2023

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Percent Change From Baseline in Fasting TG at Week 24

Full Analysis Set: All randomized participants who received at least 1 dose of investigational product (IP) during the study period, analyzed according to the treatment assigned at randomization.Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, Week 24

ID	Title	Description
OG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) at Day 1 and Week 12 injection during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG002	ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG003	ARO-ANG3 200 mg	ARO-ANG3 200 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.

Units	Counts
Participants	OG00047 OG00147 OG00247 OG003

Title

Denominators

Categories

Title	Measurements
	OG0007.55± 3.774 OG001-43.67± 3.770 OG002-49.01± 3.777 OG003

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001		Mixed Models Repeated Measures (MMRM)		<.0001	Model includes treatment arm, study visit, randomization stratification factor (LDL-C at Screening [≥100 mg/dL vs <100 mg/dL]),and baseline value as model terms. Model also includes treatment by visit and treatment by baseline as interaction terms.	Difference vs. Placebo at Week 24	-51.22			2-Sided	95	-61.73	-40.70			ARO-ANG3 - Placebo		Superiority

Secondary

Percent Change From Baseline in Fasting TG Over Time

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization. Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, up to Week 36 (double-blind treatment period)

ID	Title	Description
OG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) at Day 1 and Week 12 injection during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG002	ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG003	ARO-ANG3 200 mg

Secondary

Percent Change From Baseline in Fasting Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization.Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, Week 24

ID	Title	Description
OG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) at Day 1 and Week 12 injection during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG002	ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG003	ARO-ANG3 200 mg

Secondary

Percent Change From Baseline in Fasting Non-HDL-C Over Time

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization. Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, up to Week 36 (double-blind treatment period)

ID	Title	Description
OG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) injection for Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG002	ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG003	ARO-ANG3 200 mg

Secondary

Percent Change From Baseline in Fasting Total Apolipoprotein B (ApoB) at Week 24

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization.Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, Week 24

ID	Title	Description
OG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG002	ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG003	ARO-ANG3 200 mg

Secondary

Percent Change From Baseline in Fasting Total ApoB Over Time

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization. Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, up to Week 36 (double-blind treatment period)

ID	Title	Description
OG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) at Day 1 and Week 12 injection during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG002	ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG003	ARO-ANG3 200 mg

Secondary

Percent Change From Baseline in Fasting Low-density Lipoprotein-Cholesterol (LDL-C) Using Ultracentrifugation at Week 24

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization.Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, Week 24

ID	Title	Description
OG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) injection for Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG002	ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG003	ARO-ANG3 200 mg

Secondary

Percent Change From Baseline in Fasting LDL-C Using Ultracentrifugation Over Time

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization. Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, up to Week 36 (double-blind treatment period)

ID	Title	Description
OG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) at Day 1 and Week 12 injection during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG002	ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG003	ARO-ANG3 200 mg

Secondary

Percent Change From Baseline in Angiopoietin-like Protein 3 (ANGPTL3) at Week 24

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization.Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, Week 24

ID	Title	Description
OG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG002	ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG003	ARO-ANG3 200 mg

Secondary

Percent Change From Baseline in ANGPTL3 Over Time

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization. Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, up to Week 36 (double-blind treatment period)

ID	Title	Description
OG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) at Day 1 and Week 12 injection during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG002	ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG003	ARO-ANG3 200 mg

Secondary

Percent Change From Baseline in Fasting High-Density Lipoprotein-Cholesterol (HDL-C) at Week 24

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization.Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, Week 24

ID	Title	Description
OG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG002	ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG003	ARO-ANG3 200 mg

Secondary

Percent Change From Baseline in Fasting HDL-C Over Time

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization. Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, up to Week 36 (double-blind treatment period)

ID	Title	Description
OG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) at Day 1 and Week 12 injection during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG002	ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG003	ARO-ANG3 200 mg

Secondary

Plasma Pharmacokinetic (PK) Concentration for ARO-ANG3 Over Time in the Double-Blind Treatment Period

Full PK Analysis Set: All participants who received at least 1 dose of active study drug and had at least 1 PK concentration data value. Observed cases.

Posted

Mean

Standard Deviation

ng/mL

Baseline, Day 1: pre-dose, 15 minutes, 1, 3, 6 hours post-dose; Day 2: 24 hours post-dose; Week 12: pre-dose, 15 minutes, 1, 3, 6, 24 hours post-dose (double-blind treatment period)

ID	Title	Description
OG000	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG002	ARO-ANG3 200 mg	ARO-ANG3 200 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.

Secondary

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and/or Serious TEAEs up to Week 24

TEAEs are adverse events (AEs) that occur following IP administration or a pre-existing condition exacerbated following IP administration. An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction.

Safety Analysis Set: All participants who received at least 1 dose of IP during the study period, analyzed according to the treatment they actually received.

Posted

Count of Participants

Participants

From first dose of IP up to Week 24

ID	Title	Description
OG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.

Secondary

Number of Participants With TEAEs and/or SAEs Over Time in the Double-Blind Treatment Period

Adverse event (AE)=any untoward medical occurrence that does not necessarily have to have a causal relationship with this treatment. TEAEs=AEs with onset after administration of the study drug, or when a pre-existing medical condition increases in severity or frequency after study drug administration. Serious adverse event (SAE)= an AE that results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction.

Safety Analysis Set: All participants who received at least 1 dose of IP during the study period, analyzed according to the treatment they actually received.

Posted

Count of Participants

Participants

up to Week 36 (double-blind treatment period)

ID	Title	Description
OG000	Placebo (Pooled)	Placebo calculated volume to match active treatment by subcutaneous (sc) injection for Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.

Secondary

Number of Participants With AEs and/or SAEs Over Time in the Open-Label Extension (OLE) Period

Safety Analysis Set: All participants who received at least 1 dose of IP during the study period, analyzed according to the treatment they actually received.

Posted

Count of Participants

Participants

From first dose of study drug in the OLE up to Month 24 (open-label extension)

ID	Title	Description
OG000	Placebo/ARO-ANG3 50mg	Placebo calculated volume to match active treatment by subcutaneous (sc) injection for Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg/ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection for up to 8 doses during the open-label extension period.

Secondary

Percent Change From Baseline in Fasting TG Over Time in the Open Label Extension (OLE) Period

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization. Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, OLE Baseline, Months 1-24 (open-label extension)

ID	Title	Description
OG000	ARO-ANG3 50 mg/ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 50 mg by sc injection during the open-label extension period.
OG001	Placebo/ARO-ANG3 50 mg	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 50 mg by sc injection during the open-label extension period.
OG002	Placebo/ARO-ANG3 100 mg	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 100 mg by sc injection during the open-label extension period.

Secondary

Percent Change From Baseline in Fasting Non-HDL-C Over Time in the Open Label Extension (OLE) Period

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization. Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, OLE Baseline, Months 1-24 (open-label extension)

ID	Title	Description
OG000	Placebo/ARO-ANG3 50 mg	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 50 mg by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg/ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 50 mg by sc injection during the open-label extension period.
OG002	Placebo/ARO-ANG3 100 mg	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 100 mg by sc injection during the open-label extension period.

Secondary

Percent Change From Baseline in Fasting Total ApoB Over Time in the Open Label Extension (OLE) Period

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization. Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, OLE Baseline, Months 1-24 (open-label extension)

ID	Title	Description
OG000	Placebo/ARO-ANG3 50 mg	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 50 mg by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg/ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 50 mg by sc injection during the open-label extension period.
OG002	Placebo/ARO-ANG3 100 mg	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 100 mg by sc injection during the open-label extension period.

Secondary

Percent Change From Baseline in Fasting LDL-C Using Ultracentrifugation Over Time in the Open Label Extension (OLE) Period

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization. Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, OLE Baseline, Months 1-24 (open-label extension)

ID	Title	Description
OG000	Placebo/ARO-ANG3 50 mg	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 50 mg by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg/ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 50 mg by sc injection during the open-label extension period.
OG002	Placebo/ARO-ANG3 100 mg	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 100 mg by sc injection during the open-label extension period.

Secondary

Percent Change From Baseline in ANGPTL3 Over Time in the Open Label Extension (OLE) Period

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization. Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, OLE Baseline, Months 1-24 (open-label extension)

ID	Title	Description
OG000	Placebo/ARO-ANG3 50 mg	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 50 mg by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg/ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 50 mg by sc injection during the open-label extension period.
OG002	Placebo/ARO-ANG3 100 mg	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 100 mg by sc injection during the open-label extension period.

Secondary

Percent Change From Baseline in Fasting HDL-C Over Time in the Open Label Extension (OLE) Period

Full Analysis Set: All randomized participants who received at least 1 dose of IP during the study period, analyzed according to the treatment assigned at randomization. Observed cases.

Posted

Least Squares Mean

Standard Error

percentage change

Baseline, OLE Baseline, Months 1-24 (open-label extension)

ID	Title	Description
OG000	Placebo/ARO-ANG3 50 mg	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 50 mg by sc injection during the open-label extension period.
OG001	ARO-ANG3 50 mg/ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 50 mg by sc injection during the open-label extension period.
OG002	Placebo/ARO-ANG3 100 mg	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 100 mg by sc injection during the open-label extension period.

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Acute myocardial infarction	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG0030 affected52 at risk EG0040 affected13 at risk EG0050 affected36 at risk EG0060 affected14 at risk EG0071 affected39 at risk EG0080 affected13 at risk EG0090 affected41 at risk
Angina unstable	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Arteriosclerosis coronary artery	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Atrial fibrillation	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Bundle branch block left	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Cardiac failure	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Coronary artery stenosis	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Myocardial infarction	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Silent myocardial infarction	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Supraventricular tachycardia	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Incarcerated umbilical hernia	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Inguinal hernia	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Pancreatitis	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Pancreatitis acute	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Small intestinal obstruction	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Death	General disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Non-cardiac chest pain	General disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
COVID-19 pneumonia	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Cellulitis	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Influenza	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Pneumonia	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Pyelonephritis	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Sepsis	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Ankle fracture	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Meniscus injury	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Diabetic ketosis	Metabolism and nutrition disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Hyperglycaemia	Metabolism and nutrition disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Hyperglycaemic hyperosmolar nonketotic syndrome	Metabolism and nutrition disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Hypoglycaemia	Metabolism and nutrition disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Musculoskeletal chest pain	Musculoskeletal and connective tissue disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Prostate cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Dizziness	Nervous system disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Syncope	Nervous system disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Transient ischaemic attack	Nervous system disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Acute kidney injury	Renal and urinary disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Acute respiratory failure	Respiratory, thoracic and mediastinal disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Chronic obstructive pulmonary disease	Respiratory, thoracic and mediastinal disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Chronic rhinosinusitis with nasal polyps	Respiratory, thoracic and mediastinal disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Dyspnoea	Respiratory, thoracic and mediastinal disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Skin ulcer	Skin and subcutaneous tissue disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Anaemia	Blood and lymphatic system disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG0033 affected52 at risk EG0040 affected13 at risk EG0051 affected36 at risk EG0061 affected14 at risk EG0070 affected39 at risk EG0080 affected13 at risk EG0093 affected41 at risk
Leukocytosis	Blood and lymphatic system disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0021 affected51 at risk EG003
Splenic cyst	Blood and lymphatic system disorders	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Angina pectoris	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Aortic valve sclerosis	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Atrial fibrillation	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Cardiac failure	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Cardiac failure congestive	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Heart failure with reduced ejection fraction	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Hypertensive heart disease	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Left ventricular dysfunction	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Mitral valve incompetence	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Myocardial ischaemia	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0021 affected51 at risk EG003
Palpitations	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0021 affected51 at risk EG003
Suprventricular tachycardia	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Tricuspid valve incompetence	Cardiac disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Ear pain	Ear and labyrinth disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Hypoacusis	Ear and labyrinth disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Cataract	Eye disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Chalazion	Eye disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Eyelid oedema	Eye disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0022 affected51 at risk EG003
Eyelid ptosis	Eye disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0012 affected50 at risk EG0020 affected51 at risk EG003
Abdominal distension	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Abdominal pain	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0011 affected50 at risk EG0022 affected51 at risk EG003
Abdominal pain upper	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Acquired oesophageal web	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Barrett's oesophagus	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Constipation	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0021 affected51 at risk EG003
Defaecation urgency	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Dental caries	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Diarrhoea	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0003 affected51 at risk EG0012 affected50 at risk EG0024 affected51 at risk EG003
Dyspepsia	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Dysphagia	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Gastritis	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Gastrooesophageal reflux disease	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0003 affected51 at risk EG0012 affected50 at risk EG0021 affected51 at risk EG003
Haemorrhoids	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0022 affected51 at risk EG003
Hiatus hernia	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0011 affected50 at risk EG0021 affected51 at risk EG003
Large intestine polyp	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0012 affected50 at risk EG0020 affected51 at risk EG003
Nausea	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0013 affected50 at risk EG0023 affected51 at risk EG003
Small intestinal obstruction	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Tooth impacted	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Toothache	Gastrointestinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0021 affected51 at risk EG003
Administration site reaction	General disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Asthenia	General disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Fatigue	General disorders	MedDRA 23.1	Systematic Assessment	EG0003 affected51 at risk EG0012 affected50 at risk EG0022 affected51 at risk EG003
Influenza like illness	General disorders	MedDRA 23.1	Systematic Assessment	EG0003 affected51 at risk EG0012 affected50 at risk EG0023 affected51 at risk EG003
Injection site bruising	General disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Injection site erythema	General disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0022 affected51 at risk EG003
Injection site induration	General disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Injection site pain	General disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0015 affected50 at risk EG0027 affected51 at risk EG003
Injection site pruritus	General disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0012 affected50 at risk EG0021 affected51 at risk EG003
Malaise	General disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Non-cardiac chest pain	General disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0013 affected50 at risk EG0023 affected51 at risk EG003
Peripheral swelling	General disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Cholelithiasis	Hepatobiliary disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Hepatic cyst	Hepatobiliary disorders	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0011 affected50 at risk EG0021 affected51 at risk EG003
Hepatic steatosis	Hepatobiliary disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0022 affected51 at risk EG003
Drug hypersensitivity	Immune system disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Acute sinusitis	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0021 affected51 at risk EG003
Asymptomatic bacteriuria	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Bronchitis	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0013 affected50 at risk EG0024 affected51 at risk EG003
COVID-19	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG00014 affected51 at risk EG00116 affected50 at risk EG00216 affected51 at risk EG003
Conjunctivitis	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0011 affected50 at risk EG0023 affected51 at risk EG003
Diverticulitis	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0013 affected50 at risk EG0020 affected51 at risk EG003
Ear infection	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Fungal skin infection	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Gastroenteritis	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0004 affected51 at risk EG0010 affected50 at risk EG0021 affected51 at risk EG003
Helicobacter gastritis	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Infective exacerbation of asthma	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Influenza	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0021 affected51 at risk EG003
Labyrinthitis	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Lower respiratory tract infection	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0004 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Nasopharyngitis	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0012 affected50 at risk EG0021 affected51 at risk EG003
Pneumonia	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0012 affected50 at risk EG0022 affected51 at risk EG003
Postoperative wound infection	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0021 affected51 at risk EG003
Pyuria	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0010 affected50 at risk EG0021 affected51 at risk EG003
Respiratory tract infection	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Sinusitis	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0004 affected51 at risk EG0013 affected50 at risk EG0020 affected51 at risk EG003
Subcutaneous abscess	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Tonsillitis	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Tooth abscess	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0012 affected50 at risk EG0020 affected51 at risk EG003
Tooth infection	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0022 affected51 at risk EG003
Upper respiratory tract infection	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0007 affected51 at risk EG0018 affected50 at risk EG0029 affected51 at risk EG003
Urinary tract infection	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0005 affected51 at risk EG0016 affected50 at risk EG0026 affected51 at risk EG003
Viral pharyngitis	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Viral upper respiratory tract infection	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0011 affected50 at risk EG0023 affected51 at risk EG003
Wound infection	Infections and infestations	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Arthropod bite	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Bone contusion	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Burns second degree	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Clavicle fracture	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Contusion	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0003 affected51 at risk EG0012 affected50 at risk EG0023 affected51 at risk EG003
Ear canal injury	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Fall	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0004 affected51 at risk EG0012 affected50 at risk EG0021 affected51 at risk EG003
Joint injury	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0021 affected51 at risk EG003
Ligament rupture	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Ligament sprain	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Limb injury	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0021 affected51 at risk EG003
Muscle strain	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0003 affected51 at risk EG0010 affected50 at risk EG0021 affected51 at risk EG003
Musculoskeletal injury	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0022 affected51 at risk EG003
Rib fracture	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Road traffic accident	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0021 affected51 at risk EG003
Skin laceration	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0003 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Soft tissue injury	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0022 affected51 at risk EG003
Tendon injury	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Wrist fracture	Injury, poisoning and procedural complications	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Amylase increased	Investigations	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Bacterial test positive	Investigations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Blood creatine phosphokinase increased	Investigations	MedDRA 23.1	Systematic Assessment	EG0003 affected51 at risk EG0011 affected50 at risk EG0021 affected51 at risk EG003
Blood glucose increased	Investigations	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0011 affected50 at risk EG0021 affected51 at risk EG003
Blood potassium decreased	Investigations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
C-reactive protein increased	Investigations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Cardiac murmur	Investigations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Gamma-glutamyltransferase increased	Investigations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Glycosylated haemoglobin increased	Investigations	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0014 affected50 at risk EG0023 affected51 at risk EG003
High density lipoprotein decreased	Investigations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Lipase increased	Investigations	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0011 affected50 at risk EG0023 affected51 at risk EG003
Low density lipoprotein increased	Investigations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Troponin increased	Investigations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Urine analysis abnormal	Investigations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
White blood cells urine positive	Investigations	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Decreased appetite	Metabolism and nutrition disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0021 affected51 at risk EG003
Diabetes mellitus	Metabolism and nutrition disorders	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0011 affected50 at risk EG0021 affected51 at risk EG003
Diabetes mellitus inadequate control	Metabolism and nutrition disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Glucose tolerance impaired	Metabolism and nutrition disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Gout	Metabolism and nutrition disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Hyperuricaemia	Metabolism and nutrition disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0012 affected50 at risk EG0020 affected51 at risk EG003
Hypoglycaemia	Metabolism and nutrition disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Type 2 diabetes mellitus	Metabolism and nutrition disorders	MedDRA 23.1	Systematic Assessment	EG0005 affected51 at risk EG0014 affected50 at risk EG0022 affected51 at risk EG003
Vitamin D deficiency	Metabolism and nutrition disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Arthralgia	Musculoskeletal and connective tissue disorders	MedDRA 23.1	Systematic Assessment	EG0004 affected51 at risk EG0013 affected50 at risk EG0024 affected51 at risk EG003
Arthritis	Musculoskeletal and connective tissue disorders	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Back pain	Musculoskeletal and connective tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0015 affected50 at risk EG0022 affected51 at risk EG003
Bursitis	Musculoskeletal and connective tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Facet joint syndrome	Musculoskeletal and connective tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Intervertebral disc protrusion	Musculoskeletal and connective tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Muscle spasms	Musculoskeletal and connective tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0022 affected51 at risk EG003
Musculoskeletal chest pain	Musculoskeletal and connective tissue disorders	MedDRA 23.1	Systematic Assessment	EG0005 affected51 at risk EG0012 affected50 at risk EG0020 affected51 at risk EG003
Musculoskeletal pain	Musculoskeletal and connective tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Myalgia	Musculoskeletal and connective tissue disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0013 affected50 at risk EG0021 affected51 at risk EG003
Neck pain	Musculoskeletal and connective tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0022 affected51 at risk EG003
Osteoarthritis	Musculoskeletal and connective tissue disorders	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0011 affected50 at risk EG0023 affected51 at risk EG003
Pain in extremity	Musculoskeletal and connective tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0012 affected50 at risk EG0023 affected51 at risk EG003
Vertebral foraminal stenosis	Musculoskeletal and connective tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Basal cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0012 affected50 at risk EG0021 affected51 at risk EG003
Lipoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Amnesia	Nervous system disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Diabetic neuropathy	Nervous system disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Dizziness	Nervous system disorders	MedDRA 23.1	Systematic Assessment	EG0003 affected51 at risk EG0013 affected50 at risk EG0024 affected51 at risk EG003
Headache	Nervous system disorders	MedDRA 23.1	Systematic Assessment	EG0006 affected51 at risk EG0016 affected50 at risk EG0023 affected51 at risk EG003
Hypokinesia	Nervous system disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Loss of consciousness	Nervous system disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0021 affected51 at risk EG003
Paraesthesia	Nervous system disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0021 affected51 at risk EG003
Sciatica	Nervous system disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0012 affected50 at risk EG0020 affected51 at risk EG003
Adjustment disorder	Psychiatric disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Anxiety	Psychiatric disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Depression	Psychiatric disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0022 affected51 at risk EG003
Insomnia	Psychiatric disorders	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0010 affected50 at risk EG0022 affected51 at risk EG003
Acute kidney injury	Renal and urinary disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Dysuria	Renal and urinary disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Haematuria	Renal and urinary disorders	MedDRA 23.1	Systematic Assessment	EG0003 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Nephrolithiasis	Renal and urinary disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0020 affected51 at risk EG003
Pollakiuria	Renal and urinary disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Renal cyst	Renal and urinary disorders	MedDRA 23.1	Systematic Assessment	EG0003 affected51 at risk EG0011 affected50 at risk EG0021 affected51 at risk EG003
Renal impairment	Renal and urinary disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Benign prostatic hyperplasia	Reproductive system and breast disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0022 affected51 at risk EG003
Asthma	Respiratory, thoracic and mediastinal disorders	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0011 affected50 at risk EG0021 affected51 at risk EG003
Chronic obstructive pulmonary disease	Respiratory, thoracic and mediastinal disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0010 affected50 at risk EG0022 affected51 at risk EG003
Cough	Respiratory, thoracic and mediastinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0013 affected50 at risk EG0020 affected51 at risk EG003
Dyspnoea	Respiratory, thoracic and mediastinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0021 affected51 at risk EG003
Nasal congestion	Respiratory, thoracic and mediastinal disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0013 affected50 at risk EG0021 affected51 at risk EG003
Obstructive sleep apnoea syndrome	Respiratory, thoracic and mediastinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0021 affected51 at risk EG003
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0011 affected50 at risk EG0022 affected51 at risk EG003
Sleep apnoea syndrome	Respiratory, thoracic and mediastinal disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0012 affected50 at risk EG0020 affected51 at risk EG003
Upper-airway cough syndrome	Respiratory, thoracic and mediastinal disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Dermatitis contact	Skin and subcutaneous tissue disorders	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Ecchymosis	Skin and subcutaneous tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Eczema	Skin and subcutaneous tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0011 affected50 at risk EG0021 affected51 at risk EG003
Hand dermatitis	Skin and subcutaneous tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0022 affected51 at risk EG003
Nail bed bleeding	Skin and subcutaneous tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Pruritus	Skin and subcutaneous tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0021 affected51 at risk EG003
Rash	Skin and subcutaneous tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Rosacea	Skin and subcutaneous tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Seborrhoeic dermatitis	Skin and subcutaneous tissue disorders	MedDRA 23.1	Systematic Assessment	EG0002 affected51 at risk EG0010 affected50 at risk EG0021 affected51 at risk EG003
Skin haemorrhage	Skin and subcutaneous tissue disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Solar lentigo	Skin and subcutaneous tissue disorders	MedDRA 23.1	Systematic Assessment	EG0000 affected51 at risk EG0012 affected50 at risk EG0020 affected51 at risk EG003
Hot flush	Vascular disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003
Hypertension	Vascular disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0012 affected50 at risk EG0022 affected51 at risk EG003
Superficial vein thrombosis	Vascular disorders	MedDRA 23.1	Systematic Assessment	EG0001 affected51 at risk EG0010 affected50 at risk EG0020 affected51 at risk EG003

ID	Title	Description
BG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
BG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
BG002	ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period.Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
BG003	ARO-ANG3 200 mg	ARO-ANG3 200 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
BG004	Total	Total of all reporting groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Placebo	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period.	1	51	4	51	41	51
EG001	ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period.	0	50	5	50	38	50
EG002	ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period.	0	51	0	51	41	51
EG003	ARO-ANG3 200 mg	ARO-ANG3 200 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period.	0	52	1	52	42	52
EG004	Placebo/ARO-ANG3 50 mg	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 50 mg by sc injection during the open-label extension period.	0	13	3	13	10	13
EG005	ARO-ANG3 50 mg/ARO-ANG3 50 mg	ARO-ANG3 50 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 50 mg by sc injection during the open-label extension period.	0	36	4	36	31	36
EG006	Placebo/ARO-ANG3 100 mg	Placebo calculated volume to match active treatment by subcutaneous (sc) injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 100 mg by sc injection during the open-label extension period.	0	14	2	14	14	14
EG007	ARO-ANG3 100 mg/ARO-ANG3 100 mg	ARO-ANG3 100 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 100 mg by sc injection during the open-label extension period.	1	39	5	39	34	39
EG008	Placebo/ARO-ANG3 200 mg	Placebo calculated volume to match active treatment by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 200 mg by sc injection during the open-label extension period.	0	13	2	13	11	13
EG009	ARO-ANG3 200mg/ARO-ANG3 200 mg	ARO-ANG3 200 mg by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 200 mg by sc injection during the open-label extension period.	0	41	5	41	34	41